79. 家族性高コレステロール血症(ホモ接合体) Homozygous familial hypercholesterolemia Clinical trials / Disease details


臨床試験数 : 142 薬物数 : 114 - (DrugBank : 29) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 18

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-003626-26-GB
(EUCTR)
14/06/200601/11/2005A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemiaA double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia Treatment of primary dyslipidemia
MedDRA version: 8;Level: PT;Classification code 10058108
Product Name: TAK-475
Product Code: TAK-475
Takeda Europe R&D Centre LtdNULLNot RecruitingFemale: yes
Male: yes
40United Kingdom
2NCT00263081
(ClinicalTrials.gov)
November 20056/12/2005Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial HypercholesterolemiaA Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia.HypercholesterolemiaDrug: Lapaquistat acetate and current lipid-lowering treatment;Drug: Current lipid-lowering treatmentTakedaNULLTerminated8 YearsN/ABoth44Phase 3United States;Canada;France;Israel;Poland;United Kingdom